The role of aspirin in the prevention of thrombotic complication of thalidomide and anthracycline-based chemotherapy for multiple myloma

Mayo Clinic Proceedings

Volumn 80, Issue 12, 2005, Pages 1568-1574

  Baz, Rachid ^a   Li, Liang ^a   Kottke Marchant, Kandice ^a   Srkalovic, Gordan ^b   McGowan, Bridget ^a   Yiannaki, Erin ^a   Karam, Mary Ann ^a   Faiman, Beth ^a   Jawde, Rony Abou ^a   Andresen, Steven ^a   Zeldis, Jerome ^c   Hussein, Mohamad A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Division of Pediatric Surgery   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTHRACYCLINE DERIVATIVE; ARACHIDONIC ACID; BENCE JONES PROTEIN; BLOOD CLOTTING FACTOR 5 LEIDEN; COLLAGEN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; RISTOCETIN; THALIDOMIDE; VINCRISTINE; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; UNITED STATES;

EID: 28544436819     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.12.1568     Document Type: Article

References (22)

1. Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160-2168.
2. Rifkin RM, Hussein MA, Gregory SA, Mohrbacher A. Updated results from a randomized multicenter trial of DVd vs VAd in patients with newly diagnosed multiple myeloma [abstract]. J Clin Oncol. 2004;14S(suppl):560s. Abstract 6509.
3. Masci P, Karam MA, Platt L, et al. A phase II trial of doxil, vincristine and reduced schedule dexamethasone (DVd) for patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2004;104:2415.
4. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
5. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-1171.
6. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607-616.
7. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
8. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003;1:445-449.
9. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126:715-721.
10. Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost. 2003;29:247-258.
11. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 2003;16:21-31.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
13. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22:1857-1863.
14. Carman TL, Deitcher SR. Advances in diagnosing and excluding pulmonary embolism: spiral CT and D-dimer measurement. Cleve Clin J Med. 2002;69:721-729.
15. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park). 2003;17:126-135, 139.
16. Jacobson JL,Hussein MA, Barlogie B, Durie BG, Crowley JJ, Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441-450.
17. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558-566.
18. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [letter]. Blood. 2002;100:2272-2273.
19. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826-831.
20. Weber D, Ginsberg C, Walker P, et al. Correlation of thrombotic/embolic events (TE) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD) [abstract]. Blood. 2002;100:209a. Abstract 787.
21. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [letter]. Leukemia. 2004;18:2044-2046.
22. Landolfi R, Marchioli R, Kutti I. et al, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.